Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...

A recently published study examined the effects of adding sitagliptin—an inhibitor of dipeptidyl peptidase 4—to therapy for patients with type 2 diabetes mellitus who were inadequately ...

Researchers from the US have shown that combination therapy with sitagliptin and metformin results in a substantial and additive glycemic improvement in patients with type 2 diabetes. Sitagliptin ...

Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug ...

Merck already has the world’s biggest selling oral treatment for type 2 diabetes, its DPP-4-based drugs Januvia and Janumet, but it is playing catch-up in the SGLT2 market. The monotherapy and ...

[31] Double-blind, placebo-controlled studies on the safety and efficacy of sitagliptin have been conducted with patients with Type 2 diabetes. Mean age was 55 and participants were of varying ...